Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine

al-Damluji S (1988) Adrenergic mechanisms in the control of corticotrophin secretion. J Endocrinol 119:5–14 al-Damluji S, Bouloux, White A, Besser M (1990) The role of alpha-2 adrenoceptors in the control of ACTH secretion; interaction with the opioid system. Neuroendocrinology 51:76–81 American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. American Psychiatric Association, Washington, DC Beckett PJ, Finch L (1982) The α1- and α2-adrenoceptor involvement in the central cardiovascular action of clonidine in the conscious renal hypertensive cat. Eur J Pharmacol 82:155–160 Bricca G, Dontenwill M; Molines A, Feldman J, Belcourt A, Bousquet P (1989) The imidazoline preferring receptor: binding studies in bovine, rat, and human brainstem. Eur J Pharmacol 162:1–9 Brown MJ, Struthers AD, Burrin JM, Di Silvio L, Brown DC (1985) The physiological and pharmacological role of presynaptic α- and β-adrenergic receptors in man. Br J Clin Pharmacol 20:649–658 Cedarbaum JM, Aghajanian GK (1976) Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane. Brain Res 112:413–419 Chapleo CB, Myers PL, Butler RCM, Doxey JC, Roach AG, Smith CFC (1983) α-Adrenoceptor reagents. 1. Synthesis of some 1,4 benzodioxans as selective presynaptic α2-adrenoceptor antagonists and potential antidepressants. J Med Chem 26:823–831 Charney DS, Heninger GR, Sternberg DE (1982) Assessment of α2 autoreceptor function in humans: effects of oral yohimbine. Life Sci 30:2033–2041 Charney DS, Heninger GR, Brier A (1984) Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:751–763 Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR (1990) Noradrenergic dysregulation in panic disorder. In: Ballenger JC (ed) Neurobiology of panic disorder. Wiley-Liss, New York, pp 91–105 Dekirmenjian H, Maas JW (1974) MHPG in plasma. Clin Chem Acta 52:203–208 Doxey JC, Roach AG, Smith CFC (1983) Studies on RX 781094: a selective, potent and specific antagonist of α2 adrenoceptors. Br J Pharmacol 78:489–505 Doxey JC, Lane AC, Roach AG, Virdee NK (1984) Comparison of the α-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine, and corynanthine. Naunyn-Schmiedeberg's Arch Pharmacol 325:136–144 Dwoskin LP, Neal BS, Sparber SB (1988) Evidence for anti-serotonergic properties of yohimbine. Pharmacol Biochem Behav 31:321–326 Elliott HL, Jones CR, Vincent J, Lawrie CB, Reid JL (1984) The alpha adrenoceptor antagonist properties of idazoxan in normal subjects. Clin Pharmacol Ther 36:190–196 Elsworth JD, Redmond DE, Jr, Roth RH (1982) Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates. Brain Res 235:115–124 Ernsberger P, Meeley MP, Mann JJ, Reis DJ (1987) Clonidine binds to imidazole binding sites as well as α2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 134:1–13 Ernsberger P, Giuliano R, Willette RN, Reis DJ (1990) Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 253:408–418 Goldberg MR, Robinson D (1983) Yohimbine: a pharmacological probe for study of the α2-adrenoreceptor. Pharmacol Rev 35:143–180 Grunhaus L, Tiongco D, Zelnik T, Flegel P, Hollingsworth PJ, Smith CB (1989) Intravenous yohimbine: selective enhancer of norepinephrine and cortisol secretion and systolic blood pressure in humans. Clin Neuropharmacol 12:106–114 Gurguis GNM, Uhde TW (1990) Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology 15:217–224 Herrick-Davis K, Titeler M, Leonhardt S, Struble R, Price D (1988) Serotonin 5-HT1D in human prefrontal cortex and caudate: interaction with a GTP binding protein. J Neurochem 51:1906–1912 Hieble JP, Sulpizio, Nichols AJ, Willette RN, Ruffolo RR, Jr (1988) Pharmacologic characterization of SK&F 104078, a novel alpha-2 adrenoceptor antagonist which discriminates between pre- and postjunctional alpha-2 adrenoceptors. J Pharmacol Exp Ther 247:645–652 Holmberg G, Gershon S (1961) Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia 2:93–106 Ingram CG (1962) Some pharmacologic actions of yohimbine and chlorpromazine in man. Clin Pharmacol Ther 3:345–352 Krystal JH, Southwick S, Charney DS (1990) Yohimbine effects in PTSD patients. 1990 CME Syllabus and Proceedings Summary, 143rd Annual Meeting, American Psychiatric Association. Abstract #54C Lacomblez L, Bensimon G, Isnard F, Diquet B, Lecrubrier Y, Puech AJ (1989) Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomip-ramine. Clin Pharmacol Ther 45:241–251 Langer SZ, Cavero I, Massinham R (1980) Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 2:372–382 Lehmann J, Koenig-Berard E, Vitou P (1989) The imidazoline-preferring receptor. Life Sci 45:1609–1615 Maas JW, Hattox SE, Roth RH (1976) The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG). Brain Res 118:167–174 Onrot J, Goldberg MR, Biaggioni I, Wiley RG, Hollister AS, Robertson D (1987) Oral yohimbine in human autonomic failure. Neurology 37:215–220 Osman OT, Rudorfer MV, Manji HK, Potter WZ (1989a) Idazoxan: a novel alpha-2 antagonist and antidepressant. In: 1989, New Research Program and Abstracts, American Psychiatric Association, 142nd Annual Meeting, (abstract: #NR52) Osman OT, Rudorfer MV, Potter WZ (1989b) Idazoxan: a selective α2-antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch Gen Psychiatry 46:958–959 Osman OT, Rudorfer MV, Manji HK, Gorssman F, Potter WZ (1990) Idazoxan in treatment-resistant bipolar depression. In: 1990, New Research Program and Abstracts, American Psychiatric Association, 143rd Annual Meeting, (abstract: #NR432) Peroutka SJ, Switzer JA, Hamik A (1989) Identification of 5-hydroxytryptamine1D binding sites in human brain membranes. Synapse 3:61–66 Pettibone DJ, Pfleuger AB, Totaro JA (1985) Comparison of the effects of recently developed α2-adrenergic antagonists with yohimbine and rauwolscine on monoamine synthesis in rat brain. Biochem Pharmacol 34:1093–1097 Price LH, Charney DS, Rubin L, Heninger GR (1986) α2-adrenergic receptor function in depression: the cortisol response to yohimbine. Arch Gen Psychiatry 43:849–858 Redmond DE, Jr (1979) New and old evidence for the involvement of a brain norepinephrine system in anxiety. In: Fann WE (ed) The phenomenology and treatment of anxiety. Plenum Press, New York, pp 153–203 Reid K, Morales A, Harris C, Surridge DH, Condra M, Owen J (1987) Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet i:421–423 Riley AJ, Goodman RE, Kellett JM, Orr R (1989) Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sex Marital Ther 4:17–26 Scatton B, Zivkivic B, Dedek J (1980) Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther 215:494–499 Scatton B, Dedek J, Zivkovic B (1983) Lack of involvement of α2-adrenoceptors in the regulation of striatal dopaminergic transmission. Eur J Pharmacol 86:427–433 Seibyl JP, Krystal JH, Price LH, Charney DS (1989) Use of yohimbine to counteract nortriptyline-induced orthostatic hypotension. Letter. J Clin Psychopharmacol 9:67–68 Starke K, Borowski E, Endo T (1975) Preferential blockade of presynaptic α-adrenoceptors by yohimbine. Eur J Pharmacol 34:385–388 Struthers AD, Burrin JM, Brown MJ (1986) Exercise-induced increases in plasma catecholamines and growth hormone are augmented by selective α2 adrenoceptor blockade in man. Neuroendocrinology 44:22–28 Sun M-K, Guyenet PG (1986) Effect of clonidine and γ-amino-butyric acid on the discharges of medullo-spinal sympathoexcitatory neurons in the rat. Brain Res 368:1–17 van Oene JC, de Vries JB, Horn AS (1984) The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 327:304–311 Waldmeier PC, Ortmann R, Bischoff S (1982) Modulation of dopaminergic transmission by alpha-noradrenergic agonists and antagonists: evidence for antidopaminergic properties of some alpha-antagonists. Experientia 38:1168–1176 Winer BJ (1971) Statistical principles in experimental design. McGraw-Hill, New York